Viral eradication reduces all-cause mortality, including non–liver-related disease, in patients with progressive hepatitis C virus-related fibrosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 3, 2017, Pages 687-694

  Tada, Toshifumi ^a   Kumada, Takashi ^a   Toyoda, Hidenori ^a   Kiriyama, Seiki ^a   Tanikawa, Makoto ^a   Hisanaga, Yasuhiro ^a   Kanamori, Akira ^a   Kitabatake, Shusuke ^a   Yama, Tsuyoki ^a   Tanaka, Junko ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

causes of death; eradication of HCV; hepatitis C; non liver related mortality; progressive liver fibrosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC HEPATITIS C; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE; VIRAL CLEARANCE; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DISEASE COURSE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS;

EID: 85015852398     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13589     Document Type: Article

References (34)

1. Adinolfi LE, Restivo L, Guerrera B et al. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis 2013; 231: 22–26.
2. Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328–333.
3. Lin YJ, Shaw TG, Yang HI, Lu SN, Jen CL, Wang LY, et al; R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. Liver Int 2016. [Epub ahead of print].
4. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 1997; 127: 875–881.
5. Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J. Hepatol. 1999; 30: 783–787.
6. Poynard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin. Liver Dis. 1999; 3: 869–881.
7. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann. Intern. Med. 1999; 131: 174–181.
8. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124–1130.
9. Hung CH, Lee CM, Lu SN et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J. Viral Hepat. 2006; 13: 409–414.
10. Hsu YC, Lin JT, Ho HJ et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293–1302.
11. Arase Y, Suzuki F, Suzuki Y et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739–744.
12. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584–2593.
13. Szabo SM, Samp JC, Walker DR et al. Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review. Ann. Hepatol. 2015; 14: 618–630.
14. Lee MH, Yang HI, Lu SN et al. R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J. Infect. Dis. 2012; 206: 469–477.
15. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–526.
16. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912–921.
17. American Association for the Study of Liver Diseases (AASLD). Published on recommendations for testing, managing, and treating hepatitis C Available at: http://www.hcvguidelines.org. Accessed on September 1, 2015.
18. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2014; 60: 392–420.
19. Omata M, Kanda T, Yu M-L et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409–435.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–1236.
21. Bruix J, Sherman M. Management ofhepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
22. World Health Organization. International Classification of Diseases (ICD). http://www.who.int/classifications/icd/en/. Accessed on September 1, 2015.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999; 94: 496–509.
24. Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015; 121: 2874–2882.
25. D'Ambrosio R, Della Corte C, Colombo M. Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int. J. Mol. Sci. 2015; 16: 19698–19712.
26. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452–458.
27. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79: 47–56.
28. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig. Liver Dis. 2014; 46: S165–173.
29. Bruno S, Di Marco V, Iavarone M et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J. Hepatol. 2016; 64: 1217–1223.
30. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015; 61: 292–302.
31. Kruger FC, Daniels CR, Kidd M et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S. Afr. Med. J. 2011; 101: 477–480.
32. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975–982.
33. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
34. Izumi N, Asahina Y, Kurosaki M et al. Inhibition of hepatocellular carcinoma by Peg IFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J. Gastroenterol. 2013; 48: 382–390.